Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bocidelpar in Mitochondrial Myopathies: NCT05217901 Clinical Landscape Report 2026
28 September 2026
NCT05217901 clinical landscape for Mitochondrial Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tadalafil in Muscular Dystrophy, Duchenne: NCT05195775 Clinical Landscape Report 2026
28 September 2026
NCT05195775 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fordadistrogene movaparvovec in Muscular Dystrophy, Duchenne: NCT05429372 Clinical Landscape Report 2026
28 September 2026
NCT05429372 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Prednisolone Acetate in Muscular Dystrophy, Duchenne: NCT05412394 Clinical Landscape Report 2026
28 September 2026
NCT05412394 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT05338099 Clinical Landscape Report 2026
28 September 2026
NCT05338099 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CRD-TMH-001 in Muscular Dystrophy, Duchenne: NCT05514249 Clinical Landscape Report 2026
28 September 2026
NCT05514249 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zeleciment Rostudirsen in Muscular Dystrophy, Duchenne: NCT05524883 Clinical Landscape Report 2026
28 September 2026
NCT05524883 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sevasemten in Muscular Dystrophy, Duchenne: NCT05540860 Clinical Landscape Report 2026
28 September 2026
NCT05540860 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delpacibart zotadirsen in Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: NCT05670730 Clinical Landscape Report 2026
28 September 2026
NCT05670730 clinical landscape for Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
Simoctocog alfa in Hemophilia A: NCT05935358 Clinical Landscape Report 2026
28 September 2026
NCT05935358 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etranacogene dezaparvovec in Hemophilia B: NCT06003387 Clinical Landscape Report 2026
28 September 2026
NCT06003387 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Simoctocog alfa in Hemophilia A: NCT05936580 Clinical Landscape Report 2026
28 September 2026
NCT05936580 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.